AstraZeneca's experimental COPD drug aced late-stage trials, boosting blockbuster sales hopes
What happened
The drug reduced flare-ups in a broader patient population than existing COPD biologics, with U.S. approval expected in early 2027
Summary assembled by rule from the sources below